{"id":50949,"date":"2022-11-16T16:02:38","date_gmt":"2022-11-16T15:02:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/"},"modified":"2022-11-16T16:02:38","modified_gmt":"2022-11-16T15:02:38","slug":"ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/","title":{"rendered":"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122"},"content":{"rendered":"
\n

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth<\/b> today announced it ranked 238 on the Deloitte Technology Fast 500<\/a>\u2122, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th<\/sup> year. AscellaHealth grew 640% during this three-year period from 2018 to 2021.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nAscellaHealth\u2019s president and chief executive officer, Dea Belazi, credits the organization\u2019s tremendous growth with its single-source, end-to-end solutions that tighten the specialty pharmacy (SP) value chain and its focus on optimizing access to expensive specialty and rare disease medications which result in improved patient outcomes. He said, “The AscellaHealth team is honored to share the spotlight with such exceptional companies and we are extremely gratified to earn this distinction. AscellaHealth is proud to offer custom solutions to pharmaceutical manufacturers and other stakeholders that enhance the lives of specialty and rare disease patients throughout the country and globally.\u201d\n<\/p>\n

\n\u201cAs the past year has shown us, innovation in important areas such as life sciences is critical to addressing infectious disease and other global health issues,\u201d said Paul Silverglate<\/a>, vice chair, Deloitte LLP and U.S. technology sector leader. \u201cIn addition, technology must keep pace with ever-changing consumer and corporate demands for faster, safer and more efficient solutions to new societal challenges. Each year I am in awe of the immense talent the Technology Fast 500 rankings reveal, confirming the winners\u2019 relentless pursuit of creativity and their ability to solve real-world problems that benefit us all.\u201d\n<\/p>\n

\n\u201cThis year\u2019s Technology Fast 500 list is a true reflection of some of today\u2019s most determined and inspiring pioneers who have prospered by anticipating what\u2019s next, understanding what\u2019s needed to succeed and driving creativity forward,\u201d said Christie Simons<\/a>, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte\u2019s audit and assurance practice. \u201cRepresenting all facets of technology, the winners have shown they not only have the vision but can also expertly manage their companies through rapid growth. We congratulate each winner on their impressive achievements.\u201d\n<\/p>\n

\nAscellaHealth previously ranked 299 as a Technology Fast 500\u2122 award winner for 2021.\n<\/p>\n

\nOverall, 2022 Technology Fast 500\u2122 companies achieved revenue growth ranging from 241% to 125,138% from 2018 to 2021, with median growth of 611%.\n<\/p>\n

\nAbout the 2022 Deloitte Technology Fast 500\u2122<\/b>\n<\/p>\n

\nNow in its 28th<\/sup> year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies \u2014 both public and private \u2014 in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.\n<\/p>\n

\nIn order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company\u2019s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.\n<\/p>\n

\nAbout AscellaHealth LLC<\/b>\n<\/p>\n

\nAscellaHealth is a global Healthcare & Specialty Pharmacy solutions organization serving patients, payers, life sciences manufacturers and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and personalized medical management services. A multiple Inc. 5000 winner and NASP 2022 Strategic Channel Partner of the Year award winner, AscellaHealth\u2019s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and\/or gene and cell therapies. Most recently, AscellaHealth has joined with its subsidiaries, Optime Care<\/a> and Terebellum<\/a> to form the AscellaHealth Family of Companies. Visit www.AscellaHealth.com<\/a>.\n<\/p>\n

\nAbout Deloitte<\/b>\n<\/p>\n

\nDeloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (\u201cDTTL\u201d), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as \u201cDeloitte Global\u201d) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the \u201cDeloitte\u201d name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com\/about<\/a> to learn more about our global network of member firms.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Nicole Dufour
\n
CPR Communications
\n
ndufour@cpronline.com<\/a>
201.641.1911 x 54\n<\/p>\n

\nMarketing:<\/b>
Darcey McDermott, Chief Marketing & Communications Officer
\n
AscellaHealth Family of Companies
\n
darcey.mcdermott@ascellahealth.com<\/a>
877.389.9040\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth today announced it ranked 238 on the Deloitte Technology Fast 500\u2122, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year. AscellaHealth grew 640% during this three-year period from 2018 to 2021. AscellaHealth\u2019s president and chief executive officer, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50949","6":"format-standard","7":"category-industry"},"yoast_head":"\nAscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth today announced it ranked 238 on the Deloitte Technology Fast 500\u2122, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year. AscellaHealth grew 640% during this three-year period from 2018 to 2021. AscellaHealth\u2019s president and chief executive officer, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-16T15:02:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221116005690\/en\/1639824\/21\/TFast500_2022_Horizontal.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122\",\"datePublished\":\"2022-11-16T15:02:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/\"},\"wordCount\":760,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005690\\\/en\\\/1639824\\\/21\\\/TFast500_2022_Horizontal.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/\",\"name\":\"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005690\\\/en\\\/1639824\\\/21\\\/TFast500_2022_Horizontal.jpg\",\"datePublished\":\"2022-11-16T15:02:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005690\\\/en\\\/1639824\\\/21\\\/TFast500_2022_Horizontal.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005690\\\/en\\\/1639824\\\/21\\\/TFast500_2022_Horizontal.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/","og_locale":"en_US","og_type":"article","og_title":"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122 - Pharma Trend","og_description":"BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth today announced it ranked 238 on the Deloitte Technology Fast 500\u2122, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year. AscellaHealth grew 640% during this three-year period from 2018 to 2021. AscellaHealth\u2019s president and chief executive officer, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-16T15:02:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221116005690\/en\/1639824\/21\/TFast500_2022_Horizontal.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122","datePublished":"2022-11-16T15:02:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/"},"wordCount":760,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005690\/en\/1639824\/21\/TFast500_2022_Horizontal.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/","url":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/","name":"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005690\/en\/1639824\/21\/TFast500_2022_Horizontal.jpg","datePublished":"2022-11-16T15:02:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221116005690\/en\/1639824\/21\/TFast500_2022_Horizontal.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221116005690\/en\/1639824\/21\/TFast500_2022_Horizontal.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ascellahealth-ranked-number-238-fastest-growing-company-in-north-america-on-the-2022-deloitte-technology-fast-500\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500\u2122"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50949"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50949\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}